MC
EW icon

Moors & Cabot’s Edwards Lifesciences EW Stock Holding History

Moors & Cabot’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$2K – 892
2024
Q1 		$2K Buy
+100
New +$8.4K ﹤0.01% 904
2023
Q3 		– Hold
0
– -$1.83K – 841
2023
Q2 		– Hold
0
– – – 839
2023
Q1 		– Hold
0
– – – 838
2021
Q3 		– Sell
-500
Closed -$13K – 883
2021
Q2 		$13K Hold
500
– – ﹤0.01% 806
2021
Q1 		$5K Buy
+500
New +$42.3K ﹤0.01% 764

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Moors & Cabot's EW Position: Q1 2026 in Review

Moors & Cabot reduced its Edwards Lifesciences (EW) stake by 1.7% in Q1 2026, selling an estimated $79.1K and leaving 54,313 shares worth $4.35M. The position accounts for 0.19% of the portfolio, ranked #114.

Moors & Cabot first reported a position in EW in Q2 2014 and has held it in 48 quarters since. The position peaked at $6.65M in Q4 2021. 1,284 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Moors & Cabot held 54,313 shares of Edwards Lifesciences worth $4.35M as of Q1 2026.
  • Moors & Cabot sold 959 Edwards Lifesciences shares in Q1 2026, an estimated $79.1K.
  • Edwards Lifesciences made up 0.19% of Moors & Cabot's portfolio in Q1 2026, its #114 holding.
  • Moors & Cabot first reported a position in Edwards Lifesciences in Q2 2014 and has held it in 48 quarters since.
  • Moors & Cabot's Edwards Lifesciences position peaked at $6.65M in Q4 2021.
  • 1,284 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Moors & Cabot's 13F filing for Q1 2026, filed 8 May 2026.